Klabax (Clarithromycin)

Clarithromycin is employed to treat bacterial infections affecting the respiratory tract, skin and gastrointestinal system.

• Community‑acquired pneumonia: eradicates the causative bacteria and improves clinical recovery.
• Acute bacterial sinusitis: reduces sinus inflammation and clears infection.
• Acute bacterial exacerbations of chronic bronchitis: shortens symptom duration and prevents complications.
• Skin and soft‑tissue infections: eliminates pathogenic bacteria and promotes wound healing.
• Helicobacter pylori eradication regimens: contributes to bacterial clearance when combined with other agents.

• Clarithromycin binds to the 50S subunit of bacterial ribosomes, blocking the translocation step of protein synthesis. This inhibition prevents elongation of the peptide chain, halting bacterial growth and leading to a bacteriostatic effect against susceptible organisms.

Clarithromycin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, sometimes watery.
• Abdominal pain: cramping or discomfort.
• Taste disturbance: metallic or bitter taste.
• Headache: mild tension‑type headache.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice.
• QT prolongation: cardiac rhythm disturbances.
• Severe allergic reaction: anaphylaxis or angioedema.
• Clostridioides difficile colitis: severe diarrhea with abdominal pain.

Before prescribing Klabax, clinicians should consider patient‑specific factors and monitoring requirements.

• Assess liver function: avoid use in severe hepatic impairment.
• Review cardiac history: caution in patients with known QT prolongation.
• Evaluate drug interactions: check concomitant medications that affect CYP3A4.
• Monitor renal function: dose adjustment may be needed in severe renal failure.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Clarithromycin interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of rhabdomyolysis.
• Certain antiarrhythmics (e.g., amiodarone, quinidine): may cause serious QT prolongation.
• Pimozide: increased plasma levels leading to neurotoxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: enhanced anticoagulant effect, monitor INR.
• Oral hypoglycemics (e.g., sulfonylureas): potential hypoglycemia, monitor glucose.
• Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce clarithromycin levels.